ALT
Altimmune, Inc.
There isn't enough reported data to score ALT yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ALT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ALT's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ALT PE Valuation
ALT has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ALT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ALT's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ALT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.71 | +$0.36 |
| Q2 2026 | -$0.77 | +$0.41 |
| Q1 2026 | -$0.92 | +$0.34 |
| Q4 2025 | -$1.00 | +$0.34 |
| Q3 2025 | -$1.07 | +$0.50 |
| Q2 2025 | -$1.18 | +$0.46 |
| Q1 2025 | -$1.26 | +$0.35 |
| Q4 2024 | -$1.34 | +$0.32 |
ALT has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ALT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $26K | +420% |
| Q3 2025 | $5K | 0% |
| Q2 2025 | $5K | 0% |
| Q1 2025 | $5K | 0% |
| Q4 2024 | $5K | -86% |
| Q3 2024 | $5K | -99% |
| Q2 2024 | $5K | -17% |
| Q1 2024 | $5K | -76% |
ALT has the stronger quarterly revenue trend. Revenue is up 420% for ALT versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -111127% | +386193 points |
| Q3 2025 | -417180% | +78160 points |
| Q2 2025 | -458440% | +76460 points |
| Q1 2025 | -436300% | +99580 points |
| Q4 2024 | -497320% | -406447 points |
| Q3 2024 | -495340% | -489114 points |
| Q2 2024 | -534900% | -234783 points |
| Q1 2024 | -535880% | -432266 points |
ALT's operating margin was −111127% last quarter, up 386193 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ALT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.8M | -$25.9M |
| Q1 2026 | -$21M | -$4.1M |
| Q4 2023 | -$16.5M | +$811K |
| Q3 2023 | -$20.5M | -$5.4M |
| Q2 2023 | -$19.4M | -$2.7M |
| Q1 2023 | -$19.5M | -$5.9M |
| Q4 2022 | -$17.3M | +$4.8M |
| Q3 2022 | -$15.1M | +$2.7M |
ALT has burned cash in almost every quarter: −$102M over the past year, against −$66M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ALT on cash generation, producing positive trailing cash flow while its opponent burns cash.
ALT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +19.8M shares |
| 1 year | +152% | +124M shares |
| 3 years | +310% | +155M shares |
| 5 years | +427% | +166M shares |
| Available history | +1464% | +192M shares |
ALT has 205M diluted shares, up 152% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ALT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ALT Net Leverage
ALT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ALT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.5 | Oversold |
| Stochastic | 4.7 | Oversold |
ALT's weekly RSI is 27 (oversold) and its Stochastic is 5 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ALT PE vs Healthcare Sector
ALT has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ALT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.31 | 30% below |
| 20 week MA | $2.77 | 42% below |
| 50 week MA | $3.33 | 52% below |
| 100 week MA | $4.23 | 62% below |
| 200 week MA | $5.48 | 71% below |
ALT is in a downtrend: it's below all five of its weekly moving averages, and 71% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ALT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.80 | $11.5 | +536% |
| 2021 | $11.5 | $9.20 | -20% |
| 2022 | $9.20 | $15.3 | +67% |
| 2023 | $15.3 | $11.3 | -27% |
| 2024 | $11.3 | $7.67 | -32% |
| 2025 | $7.67 | $3.86 | -50% |
| 2026 YTD | $3.86 | $1.61 | -58% |
ALT has finished three years in a row lower, and it's down 58% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ALT on returns for 2026, with the stronger performance.